05:50 , Jun 2, 2018 |  BioCentury  |  Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
01:04 , Dec 8, 2017 |  BC Innovations  |  Translation in Brief

ADAM and Ephrin

An October study in Nature Medicine from researchers at Harvard Medical School and the University of Montreal has shown inhibiting the cell surface protease ADAM10 could treat a form of idiopathic pulmonary fibrosis mediated by...
07:00 , Sep 15, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Kinase-inactivating mutations in EPH receptor B4 (EPHB4) as risk markers for lymphatic-related hydrops fetalis

Biomarkers TECHNOLOGY: Gene profiling Kinase-inactivating EPHB4 mutations in parents or fetuses could help predict the risk of lymphatic-related hydrops fetalis, a condition involving fluid accumulation in at least two cavities of a fetus. Exome sequencing on tissue...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Sarcoma EPH receptor B4 (EPHB4); platelet derived growth factor receptor B (PDGFRB; PDGFR1; CD140B) Patient sample and...
07:00 , Aug 1, 2011 |  BioCentury  |  Product Development

Simple fix for EGFR resistance

All non-small cell lung cancer patients on the EGFR inhibitors Tarceva erlotinib and Iressa gefitinib eventually develop resistance to the drugs and progress. A predictive model developed by a team of cancer researchers suggests simply...
08:00 , Jan 28, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) EPH receptor B4 (EPHB4) Studies in cell culture and in human bone marrow...
07:00 , Oct 23, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer ...
07:00 , Jul 16, 2007 |  BioCentury  |  Product Development

Wounds: Not open & shut

The failure of a series of wound healing agents, combined with disappointing sales for the few products that were approved, eroded interest in the space in the 1990s. But efforts now have been rekindled by...
00:44 , Jun 2, 2007 |  BC Extra  |  Clinical News

EphB4 increases proangiogenic potential of EPCs

Researchers from Institut des Vaisseaux et du Sang in Paris and colleagues reported in The Journal of Clinical Investigation that EphB4 increases the proangiogenic potential of endothelial progenitor cells (EPCs). They noted that while...
07:00 , Apr 30, 2007 |  BioCentury  |  Strategy

MedImmune chronicles

MedImmune chronicles Since late 2000, MedImmune's stock performance has lagged its peers, as gauged by a price-weighted index consisting of Amgen (AMGN), Biogen Idec (BIIB), Genentech (DNA), Genzyme (GENZ) and Gilead (GILD). In fact, prior to...